AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTYCredit Agreement and Guaranty • May 22nd, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • New York
This AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY, dated as of April 27, 2020 (this “Amendment”), is among ArcherDX, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto (the “Lenders”), and Perceptive Credit Holdings II, LP, a Delaware limited partnership, as the administrative agent and collateral agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”). Reference is made to the Credit Agreement and Guaranty, dated as of May 10, 2019 (as amended or otherwise modified, the “Credit Agreement”), among the Borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and the Administrative Agent. Capitalized terms used herein without definition shall have the same meanings as set forth in the Credit Agreement, as amended hereby.
ContractMaster Services Agreement • May 22nd, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE ARCHERDX, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ARCHERDX, INC. IF PUBLICLY DISCLOSED.
IN VITRO DIAGNOSTICS MASTER COLLABORATION AGREEMENT between ASTRAZENECA UK LIMITED and ARCHERDX, INCMaster Collaboration Agreement • May 22nd, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Delaware
This In Vitro Diagnostics Master Collaboration Agreement (this “Agreement”) is made and entered into effective as of 2020 (the “Effective Date”), by and between AstraZeneca UK Limited, a company incorporated in England under no. 03674842 whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, England (“AZ”), and ArcherDX, INC ., a company incorporated in Delaware whose principal office is at 2477 55th Street, Suite 202 Boulder, CO 80301, USA (“Company”). AZ and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
MASTER CDX AGREEMENT Dated 19 September, 2018 between Merck KGaA andMaster CDX Agreement • May 22nd, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances
This Master CDx Agreement (this “Agreement”) is dated as of 19 September, 2018 (the “Effective Date”) by and between ArcherDX, Inc., a corporation organized under the laws of the State of Delaware having a place of business at 2477 55th Street, Suite 202, Boulder, CO 80301, United States of America (“ArcherDX”), and Merck KGaA, a corporation with general partners organized under German law having a place of business at Frankfurter Straße 250, 64293 Darmstadt, Germany (“MRK”). ArcherDX and MRK may be referred to herein as a “Party” or, collectively, as “Parties”.
MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • May 22nd, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • New York
This Master Collaboration Agreement (this “Agreement”) is made effective as of December 6, 2017 (the “Effective Date”), by and between Archer DX, Inc. a Delaware corporation with offices at 2477 55th Street, Suite 202, Boulder, CO 80301 USA (“ARCHER”), and Merck KGaA, a corporation with general partners under German law, with offices at Frankfurter Strasse 250, 64293 Darmstadt, Germany (including its Affiliates, “MRK”). MRK and ARCHER are each sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE ARCHERDX, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ARCHERDX, INC. IF PUBLICLY DISCLOSED.Ivd Collaboration Agreement • May 22nd, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Delaware
This IVD Collaboration Agreement (this “Agreement”) is effective as of the date of last signature below (the “Effective Date”) between Illumina, Inc., a Delaware corporation, having a place of business at 5200 Illumina Way, San Diego, CA 92122 (“Illumina”) and ArcherDx, a Delaware corporation, having a place of business at 2477 55th St.# 202 Boulder, CO 80301 (“ArcherDx”). Illumina and ArcherDx may each be referred to individually as a “Party” and collectively as the “Parties.”
